Therapie des unbehandelten lokal fortgeschrittenen oder metastasierten Nierenzellkarzinoms
- 10 September 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Der Urologe
- Vol. 54 (10), 1443-1445
- https://doi.org/10.1007/s00120-015-3946-5
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.Journal of Clinical Oncology, 2015
- Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2014
- Overall Survival in Renal-Cell Carcinoma with Pazopanib versus SunitinibNew England Journal of Medicine, 2014
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabJournal of Clinical Oncology, 2014
- SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).Journal of Clinical Oncology, 2014
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2013
- Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinomaCancer Treatment Reviews, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010